Track record · closed signal

Eli Lilly and Company (LLY) — closed signal from April 23, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on July 22, 2026 — +26% at the close.

Predicted vs. what happened

LLY price · publication thesis → realized outcomesplit-adjusted

$905.00 – $930.00Entry zone — fair-value band

$923.24Published — price the day we called it

$1,089.42Target — the price the thesis aimed for

$1,249.45Peak — highest point inside the window, not a realized return

$1,163.01Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 34 days.

At window close

+26%

realized, from the publication price to the last close inside the window

Peak gain

+35.3%

peak, from the publication price — not a realized return

S&P 500, same window

+5.8%

SPY over the identical days, dividend-adjusted

Window close

$1,163.01

last close inside the window, ended July 22, 2026

Peak price

$1,249.45

peak on July 7, 2026 — not a realized return

Days to target

The thesis — published April 23, 2026

Predicted growth

+18%

over the measurement window

Target price

$1,089.42

the price the thesis aimed for

Entry zone

$905.00 – $930.00

the fair-value band we waited for

Price at publication

$923.24

published April 23, 2026

Confidence

82%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Lilly looks strong for the next 0-3 months because the company is executing well: sales and profits are growing and the stock price is not unusually high compared with its recent direction. That mix-solid business results plus a price near typical trend levels-helps justify a positive view even though the stock is priced richly. The story is based on steady business performance rather than waiting for a big news event.

Primary drivers

Reliable growth in sales and profits from key medicines
Share price sits close to its recent trend, not far above
Thesis rests on steady execution rather than headlines
Strong growth profile helps the stock hold up short-term

How it played out

LLY: target reached in 34 days

Lyra published a positive short-term thesis on April 23, with expected growth of 18% from a price of $923.24 toward $1,089.42. The thesis pointed to reliable sales and profit growth from key medicines, a share price near its recent trend, and steady execution rather than a major news event.

The shares reached the target in 34 days. They later peaked at $1,249.45 on July 7, a gain of 35.3%. The window ended with the price at $1,163.01, still above the target. The thesis played out and exceeded its stated price objective.

What happened during the window

On April 30, Lilly reported first-quarter 2026 results and raised its full-year guidance. On May 6, the company announced an additional $4.5 billion investment across two Indiana manufacturing sites.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All LLY signals